Herbert E Ward

Herbert E Ward, M.D.

Associate Professor

Department: MD-PSYCHIATRY
Business Phone: (352) 265-4357
Business Email: hward@ufl.edu

About Herbert E Ward

Dr. Ward has served as the medical director for the department, medical director for the VA PTSD program, director of psychiatric specialty clinics, co-director of the UF Weight Management Program, and interim director for our general adult clinic. In addition, he has chaired four faculty search committees, the Anxiety Disorders Program Development Committee, and the Weight Management Program Development Committee. Currently, Herbert Ward, M.D. is on the Shands at UF Executive Committee and continues to be both a role model for medical psychiatry but also actively involved in bringing evidence-based practices to UF College of Medicine, clinics and inpatient psychiatric settings.

Herbert Ward, M.D. received a Masters in neuropharmacology before attending medical school at the Medical University of South Carolina. He completed a combined residency training program in internal medicine and psychiatry from West Virginia University which lead to board certification in both specialties. His training in a med/psych clinical environment serves as a background for his current appointment as the vice chair for clinical services and chief of adult clinics and clinical services. He is an expert in internal medicine and psychiatry and their area of overlap. Areas of special interest include diagnosis and treatment of anxiety and depressive disorders in the outpatient , medical, and primary care settings. Dr. Ward’s commitment to medical education has been recognized through his receipt of the NIMH Faculty Scholar Award early in his career and Faculty Teaching Awards from two different universities. Administrative experience at UF has included serving as the acting director of psychiatry for UF Student Health, medical director for the Department of Psychiatry and director of the psychiatry specialty clinics. Dr. Ward’s combined training in internal medicine and psychiatry, investment in clinical teaching and administrative experience make him uniquely qualified for this position.

 

Accomplishments

Founder Award
2019 · UF Health Norman Fixel Institute for Neurological Diseases
Endowed Kaine Professorship
2016 · University of Florida, College of Medicine
Exemplary Teacher Award
2016 · Department of Psychiatry, University of Florida
Resident Mentor Award
2016 · Department of Psychiatry, University of Florida
Teacher of the Year Award
1998 · Department of Psychiatry, University of Florida
Faculty Teaching Award
1993 · Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine
  • Psychiatry
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Medicine
  • Psychiatry
Areas of Interest
  • Deep brain stimulation
  • Generalized anxiety disorder
  • Major depression
  • Major depression with psychotic features
  • Obesity
  • Obsessive-compulsive disorder
  • Obsessive-compulsive personality disorder
  • Panic disorder
  • Seasonal affective disorder
  • Transcranial Magnetic Stimulation (TMS)

Publications

2021
Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial.
Biological psychiatry. 90(10):721-728 [DOI] 10.1016/j.biopsych.2021.04.019. [PMID] 34274108.
2021
Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design.
Contemporary clinical trials communications. 22 [DOI] 10.1016/j.conctc.2021.100785. [PMID] 34189335.
2021
Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial
World Psychiatry. 20(3):397-404 [DOI] 10.1002/wps.20905. [PMID] 34505368.
2021
The Decline of Deep Brain Stimulation for Obsessive-Compulsive Disorder Following FDA Humanitarian Device Exemption Approval.
Frontiers in surgery. 8 [DOI] 10.3389/fsurg.2021.642503. [PMID] 33777998.
2019
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial.
The American journal of psychiatry. 176(11):931-938 [DOI] 10.1176/appi.ajp.2019.18101180. [PMID] 31109199.
2017
Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders.
Movement disorders clinical practice. 4(2):191-197 [DOI] 10.1002/mdc3.12382. [PMID] 28944256.
2016
Interdisciplinary Parkinson’s Disease Deep Brain Stimulation Screening and the Relationship to Unintended Hospitalizations and Quality of Life.
PloS one. 11(5) [DOI] 10.1371/journal.pone.0153785. [PMID] 27159519.
2016
Overview of the Current Use of Deep Brain Stimulation in Psychiatric Disorders
Psychiatric Annals. 46(11):631-636 [DOI] 10.3928/00485713-20161003-01.
2016
Scheduled, intermittent stimulation of the thalamus reduces tics in Tourette syndrome.
Parkinsonism & related disorders. 29:35-41 [DOI] 10.1016/j.parkreldis.2016.05.033. [PMID] 27297737.
2016
Six-Nine Year Follow-Up of Deep Brain Stimulation for Obsessive-Compulsive Disorder.
PloS one. 11(12) [DOI] 10.1371/journal.pone.0167875. [PMID] 27930748.
2015
Impact of an Interdisciplinary Deep Brain Stimulation Screening Model on Post-Surgical Complications in Essential Tremor Patients.
PloS one. 10(12) [DOI] 10.1371/journal.pone.0145623. [PMID] 26710099.
2014
Acute and Chronic Mood and Apathy Outcomes from a randomized study of unilateral STN and GPi DBS.
PloS one. 9(12) [DOI] 10.1371/journal.pone.0114140. [PMID] 25469706.
2014
An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting.
PloS one. 9(3) [DOI] 10.1371/journal.pone.0091545. [PMID] 24646688.
2014
Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery.
Journal of Parkinson's disease. 4(4):591-8 [DOI] 10.3233/JPD-140357. [PMID] 25035311.
2013
A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms.
JAMA neurology. 70(1):85-94 [DOI] 10.1001/jamaneurol.2013.580. [PMID] 23044532.
2013
Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson’s disease.
Neurocase. 19(6):587-91 [DOI] 10.1080/13554794.2012.713490. [PMID] 22934916.
2013
Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington’s disease.
Stereotactic and functional neurosurgery. 91(2):129-33 [DOI] 10.1159/000341070. [PMID] 23343665.
2013
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease.
Journal of neurology. 260(2):521-7 [DOI] 10.1007/s00415-012-6669-1. [PMID] 23007193.
2012
Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson’s disease?
The Journal of neuropsychiatry and clinical neurosciences. 24(3):326-30 [DOI] 10.1176/appi.neuropsych.11090210. [PMID] 23037646.
2012
Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome.
PloS one. 7(1) [DOI] 10.1371/journal.pone.0029768. [PMID] 22295068.
2012
Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues.
Brain stimulation. 5(4):599-604 [DOI] 10.1016/j.brs.2011.10.004. [PMID] 22305344.
2011
Addiction-like manifestations and Parkinson’s disease: a large single center 9 -year experience
The Journal of Neuroscience. 122(3):145-153
2011
Do patient’s get angrier following STN, GPi, and thalamic deep brain stimulation.
NeuroImage. 54 Suppl 1:S227-32 [DOI] 10.1016/j.neuroimage.2010.09.077. [PMID] 20932923.
2011
Do stable patients with a premorbid depression history have a worse outcome after deep brain stimulation for Parkinson disease?
Neurosurgery. 69(2):357-60; discussion 360 [DOI] 10.1227/NEU.0b013e3182160456. [PMID] 21415789.
2011
Smile and Laughter Induction and Intraoperative Predictors of Response To Deep Brain Stimulation for Obsessive-Compulsive Disorder
NeuroImage. 54:S247-S255 [DOI] 10.1016/j.neuroimage.2010.03.009. [PMID] 20226259.
2010
A Case of Mania Following Deep Brain Stimulation for Obsessive Compulsive Disorder
Stereotactic and Functional Neurosurgery. 88(5):322-328 [DOI] 10.1159/000319960. [PMID] 20714212.
2010
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
The American journal of psychiatry. 167(3):281-8 [DOI] 10.1176/appi.ajp.2009.09020186. [PMID] 20008946.
2010
Deep Brain Stimulation for Intractable Obsessive Compulsive Disorder: Pilot Study Using a Blinded, Staggered-Onset Design
Biological Psychiatry. 67(6):535-542 [DOI] 10.1016/j.biopsych.2009.11.028. [PMID] 20116047.
2010
Lack of benefit of accumbens/capsular deep brain stimulation in a patient with both tics and obsessive-compulsive disorder.
Neurocase. 16(4):321-30 [DOI] 10.1080/13554790903560422. [PMID] 20178034.
2010
Prevalence of Twiddler’s syndrome as a cause of deep brain stimulation hardware failure.
Stereotactic and functional neurosurgery. 88(6):353-9 [DOI] 10.1159/000319039. [PMID] 20861658.
2010
Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial.
Psychiatry research. 178(3):467-74 [DOI] 10.1016/j.psychres.2010.05.009. [PMID] 20643486.
2010
Update on deep brain stimulation for neuropsychiatric disorders.
Neurobiology of disease. 38(3):346-53 [DOI] 10.1016/j.nbd.2010.01.011. [PMID] 20096357.
2009
A Small Pilot Study of Smile Induction in the Nih Ocd Dbs Cohort: a Potential Predictor of Therapy Response?
Annals of Neurology. 66:S78-S79
2009
Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial.
Annals of neurology. 65(5):586-95 [DOI] 10.1002/ana.21596. [PMID] 19288469.
2008
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders
Brain Stimulation. 1(2):112-121
2008
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders.
Brain stimulation. 1(2):112-21 [DOI] 10.1016/j.brs.2008.02.001. [PMID] 20633378.
2008
Neurobiological and Clinical Effects of Combining Two Antidepressant Medications From the Start
International Journal of Neuropsychopharmacology. 11:9-10
2007
Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
Journal of psychiatric research. 41(3-4):332-7 [PMID] 16860338.
View on: PubMed
2006
Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder.
Depression and anxiety. 23(7):429-33 [PMID] 16841343.
View on: PubMed
2004
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
Biological psychiatry. 55(5):553-5 [PMID] 15023585.
View on: PubMed
2003
Depression and cardiovascular disease
. 16:221-225
2002
Toward optimal treatments for major depression.
CNS spectrums. 7(2):148-50, 153 [PMID] 15220857.
View on: PubMed
2001
Understanding generalized anxiety disorder
Academic Emergency Medicine. 52(7):62-72
2000
Effects of prenatal stress on defensive withdrawal behavior and corticotropin releasing factor systems in rat brain.
Physiology & behavior. 70(3-4):359-66 [PMID] 11006435.
View on: PubMed
1999
Depression in the medical setting: biopsychological interactions and treatment considerations.
The Journal of clinical psychiatry. 60 Suppl 4:40-55; discussion 56 [PMID] 10086482.
View on: PubMed
1998
Corticotropin-releasing factor and defensive withdrawal: inhibition of monoamine oxidase prevents habituation to chronic stress.
Pharmacology, biochemistry, and behavior. 60(1):209-15 [PMID] 9610944.
View on: PubMed
1998
Psychiatric morbidity in endocrine disorders.
The Psychiatric clinics of North America. 21(2):473-89 [PMID] 9670238.
View on: PubMed
1998
Religious knowledge and its use in psychiatry
Journal of Religion & Health. 37(1):5-8
1998
The Newer Antidepressants
. 49(8):349-357
1997
Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
The Journal of clinical psychiatry. 58 Suppl 5:32-49 [PMID] 9184625.
View on: PubMed
1996
Depression in the medically ill: management considerations.
Depression and anxiety. 4(4):199-208 [PMID] 9166652.
View on: PubMed
1995
Prenatal stress increases corticotropin-releasing factor (CRF) content and release in rat amygdala minces
Brain Research. 675(1):297-302
1993
An animal model for anxiety: Effects of corticotropin releasing factor and chronic stress
. 2:33-38
1981
Antagonism of methylphenidateinduced behavior by neostigmine or hemicholinium3
Neuropharmacology. 20(7):703-709
1981
Synthesis and preliminary pharmacology of an internal standard for assay of neostigmine
Journal of Pharmaceutical Sciences. 70(4):433-435
1980
A Pharmacology experiment to demonstrate the cardiovascular effects of drugs in the rat in situ
American Journal of Pharmaceutical Education. 44:43-45

Grants

Jul 2016 ACTIVE
The Human Thalamocortical Network in tourette syndrome
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Jan 2015 – Jul 2017
A Responsive Closed-Loop Approach to Treat Freezing of Gait in Parkinsons Disease
Role: Project Manager
Funding: FOX FOU, MICHAEL J
Nov 2014 – Oct 2018
TSA Centers of Excellence for Tourette Syndrome & Tic Disorders
Role: Project Manager
Funding: TOURETTE ASSOCIATION OF AMERICA
Feb 2014 – Feb 2018
A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) in Obsessive-Compulsive Subjects
Role: Principal Investigator
Funding: BRAIN RESEARCH AND DEVELOPMENT SERVICES
Feb 2014 – Mar 2020
A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) (with the H-ADD Coil) intended as an aid to Smoking Cessation
Role: Principal Investigator
Funding: BRAIN RESEARCH AND DEVELOPMENT SERVICES
Aug 2012 – Nov 2017
ADvance: A 12-month double-blind, randomized, controlled feasibility study to evaluate the safety, efficacy and tolerability of deep brain stimulation of the fornix (DBS-f) in patients with mild probable Alzheimers disease
Role: Project Manager
Funding: FUNCTIONAL NEUROMODULATION

Education

Residency – Psychiatry
1989 · West Virginia University
Residency – Internal Medicine
1988 · West Virginia University
Internship – Psychiatry
1985 · West Virginia University
Medical Degree
1984 · University of South Carolina
Master of Science – Pharmacology
1980 · University of South Carolina
Bachelor of Science – Biology
1976 · Francis Marion University

Teaching Profile

Courses Taught
2016-2018
MDT7840 Elect Top/Psychiatry
2018
MDC7830 Psychiatry Clerkship

Contact Details

Phones:
Business:
(352) 265-4357
Emails:
Business:
hward@ufl.edu